omniture
腾盛博药

Latest News

Brii Bio Presents New Data from Its Ongoing Phase 2 Chronic Hepatitis B Trials at EASL™ Congress 2024

New translational data demonstrate that BRII-179-induced immune responses are associated with high ...

2024-06-07 19:00 2403

Brii Biosciences Provides Corporate Update and Reports Full-Year 2023 Financial Results

Transitioning HBV cure programs into multiple late-stage combination studies with interim results t...

2024-03-22 19:00 3992

Brii Biosciences Announces Agreement to Acquire VBI's IP Rights in BRII-179 (VBI-2601) and Plans to Initiate Technology Transfer to Expand Clinical and Commercial Supplies

Acquiring all intellectual properties relating to BRII-179 and eliminating future milestone and roy...

2024-02-14 08:07 4120

Brii Biosciences Appoints Dr. Brian Alvin Johns as Chief Scientific Officer

DURHAM, N.C., and BEIJING, Jan. 3, 2024 /PRNewswire/ -- Brii Biosciences Limited

2024-01-03 20:00 5149

Brii Bio Presents New Data Highlighting Progress Towards Achieving HBV Functional Cure at AASLD's The Liver Meeting® 2023

Direct evidence that BRII-179-induced functional antibody responses can contribute to increased an...

2023-11-14 06:40 1560

Brii Bio Presents New Data Highlighting Progress Towards Achieving HBV Functional Cure at AASLD's The Liver Meeting® 2023

Direct evidence that BRII-179-induced functional antibody responses can contribute to increased an...

2023-11-14 06:40 1896

Brii Biosciences Announces Topline Interim Results of Phase 2 Study Evaluating BRII-179 (VBI-2601) in Combination with PEG-IFNα for the Treatment of Chronic Hepatitis B

BRII-179 (VBI-2601) as an add-on therapy to standard of care PEG-IFNα increases HBsAg loss rate at ...

2023-09-06 18:45 2422

Brii Biosciences Provides Corporate Updates and Reports 2023 Interim Results

First patient dosed in a PEG-IFN-α controlled BRII-835 + PEG-IFN-α combination Phase 2 study for HB...

2023-08-22 22:00 3324

Brii Biosciences Broadens its Leadership in Hepatitis B with a Portfolio Now Addressing Disease's Burdens from Prevention to Cure

Extension of BRII-179 license from VBI Vaccines to global rights bolsters Brii Bio's position to ac...

2023-07-06 07:25 3033

Brii Biosciences Provides Latest Clinical Development and Corporate Updates

Company extends BRII-179 license to global rights and introduces preventive vaccine, PreHevbri® in ...

2023-07-06 07:19 2999

Brii Biosciences Announces Entry into Definitive Agreements from Sale of its Equity Interest in Qpex Biopharma and Acquiring Exclusive Global Rights for BRII-693

Company acquires exclusive global rights of the novel lipopeptide BRII-693 for the difficult to tre...

2023-06-26 07:30 2684

Brii Bio Announces New Data from Partners Underscoring Potential for HBV Functional Cure at EASL™ Congress 2023

Late-breaking data from BRII-835 + PEG-IFN-a study demonstrate anti-HBs titers at the end of treatm...

2023-06-25 20:00 3562

Brii Biosciences Announces First Subject Dosed in Phase 1 Clinical Trial of BRII-297, Long-Acting Injectable for the Treatment of Anxiety and Depressive Disorders

BRII-297, a first-of-its-kind treatment option for anxiety and depressive disorders, has the potent...

2023-06-01 08:00 2876

Brii Bio Publishes 2022 Environmental, Social and Governance Report

Brii Bio receives an "A" grade in the latest MSCI ESG Rating DURHAM, N.C. and BEIJING, April 28, 20...

2023-04-28 09:00 2959

Brii Biosciences Provides Corporate Update and Reports Full-Year 2022 Financial Results

Company maintains priority focus on clinical programs to develop a novel f unctional cure for hepati...

2023-03-24 13:33 3891

Brii Biosciences Provides Update on Strategic Clinical Development Progress

Topline Phase 2 data from multiple hepatitis B viral (HBV) infection functional cure combination st...

2022-12-27 20:00 3214

Brii Biosciences Presents Promising Clinical Data to Support Ongoing Development of Novel HIV Therapeutic Candidates at IDWeek 2022

* Findings from two Phase 1 studies show both BRII-732 and BRII-778 are safe and well-tolerated ...

2022-10-19 20:00 2130

Brii Biosciences Announces Top-line Results from Phase 1 Study of BRII-296, A Long-Acting Therapy in Development for Postpartum Depression

* Data demonstrated that a single administration of BRII-296 at 600 mg delivered a favorable phar...

2022-09-26 20:00 2423

Brii Biosciences Appoints Taiyin Yang to Board of Directors, Strengthening Product Quality Oversight to Support Company Momentum

Addition increases diversity of Board governance and supports further independent expertise DURHAM...

2022-09-01 07:30 2758
123